← Back to Search

Behavioural Intervention

Text Message Reminders for Breast Cancer Medication Adherence

N/A

Waitlist Available

Led By Margaret Barton-Burke, PhD, RN

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance) >/= 18 years of age

Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)

Must not have

History of taking palbociclib (Ibrance)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether text reminders can help people remember to take their cancer medication.

Who is the study for?

This trial is for adults with breast cancer who are starting palbociclib treatment and own a smartphone. They must be able to use the OhMD app, speak English, and manage their own healthcare without relying on caregivers.

What is being tested?

The study tests if text message reminders via the OhMD app can help patients remember to take their medication palbociclib as scheduled, compared to using a paper drug diary.

What are the potential side effects?

Since this trial focuses on the method of reminding rather than the medication itself, there are no direct side effects from the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older and starting treatment with Ibrance for breast cancer.

Select...

I am starting Ibrance for the first time, alone or with Femara or Faslodex.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have taken the medication Ibrance.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Accuracy rate of medication self-administration

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Standard of Care + InterventionExperimental Treatment1 Intervention

Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention

Group II: Standard of CareActive Control1 Intervention

Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care

0 / 3Eligibility criteria met